Impact of eptinezumab on work productivity beyond reductions in monthly migraine days: Post hoc analysis of the DELIVER trial

被引：2
|
作者：
Barbanti, Piero [1 ]
Awad, Susanne F. [2 ]
Regnier, Stephane A. [2 ]
Lee, Xin Ying [2 ]
Goadsby, Peter J. [3 ,4 ]
机构：
[1] IRCCS San Raffaele, Headache & Pain Unit, Milan, Italy
[2] H Lundbeck & Co AS, Valby, Denmark
[3] Kings Coll London, NIHR Kings Clin Res Facil, London, England
[4] Kings Coll London, Headache Grp, London, England
来源：
NEUROLOGY | 2023年 / 100卷 / 17期
关键词：
D O I：
10.1212/WNL.0000000000202965
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P13-12.012
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Rimegepant 75 mg is Associated With Significant Reductions in Monthly Migraine Days: Post-Hoc Analyses of a Multicenter, Open Label Long-Term Safety Study of Rimegepant for the Acute Treatment of Migraine
    McGinley, J. S.
    L'Italien, G. J.
    Thiry, A. C.
    Croop, R.
    Coric, V
    Lipton, R. B.
    HEADACHE, 2020, 60 : 118 - 120
  • [22] Intravenous fluids for migraine: a post hoc analysis of clinical trial data
    Balbin, Jerome Edward B.
    Nerenberg, Rebecca
    Baratloo, Alireza
    Friedman, Benjamin W.
    AMERICAN JOURNAL OF EMERGENCY MEDICINE, 2016, 34 (04): : 713 - 716
  • [23] Beyond migraine headache day reduction: Clinically meaningful improvement in disability (MIDAS score) in the absence of greater than 50% reductions in monthly migraine days with galcanezumab
    Vargas, Bert
    Starling, Amaal
    Nicholson, Robert
    Polavieja, Pepa
    Katsarava, Zaza
    Viktrup, Lars
    Vincent, Maurice
    Lipton, Richard
    NEUROLOGY, 2023, 100 (17)
  • [24] Optimization of acute medication use following eptinezumab initiation during a migraine attack: post hoc analysis of the RELIEF study
    Cady, Roger
    Lipton, Richard B.
    Buse, Dawn C.
    Josiassen, Mette Krog
    Lindsten, Annika
    Ettrup, Anders
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (01):
  • [25] Optimization of acute medication use following eptinezumab initiation during a migraine attack: post hoc analysis of the RELIEF study
    Roger Cady
    Richard B. Lipton
    Dawn C. Buse
    Mette Krog Josiassen
    Annika Lindsten
    Anders Ettrup
    The Journal of Headache and Pain, 2022, 23
  • [26] Eptinezumab Improved Work Productivity in Adults With Migraine and Prior Preventive Treatment Failures: Results From the Randomized, Double-Blind, Placebo-Controlled DELIVER Study
    Goadsby, P.
    Barbanti, P.
    Lambru, G.
    Ettrup, A.
    Christoffersen, C. L.
    Josiassen, K.
    Phul, R.
    Sperling, B.
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [27] Measuring dose-related efficacy of eptinezumab for migraine prevention: Post hoc analysis of PROMISE-1 and PROMISE-2
    Apelian, R. G.
    Boyle, L.
    Hirman, J.
    Asher, D.
    HEADACHE, 2022, 62 : 151 - 152
  • [28] Measuring dose-related efficacy of eptinezumab for migraine prevention: post hoc analysis of PROMISE-1 and PROMISE-2
    Apelian, Rami
    Boyle, Lee
    Hirman, Joe
    Asher, Divya
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (01):
  • [29] Measuring dose-related efficacy of eptinezumab for migraine prevention: post hoc analysis of PROMISE-1 and PROMISE-2
    Rami Apelian
    Lee Boyle
    Joe Hirman
    Divya Asher
    The Journal of Headache and Pain, 2022, 23
  • [30] Effects of eptinezumab on self-reported work productivity in adults with migraine and prior preventive treatment failure in the randomized, double-blind, placebo-controlled DELIVER study
    Barbanti, Piero
    Goadsby, Peter J.
    Lambru, Giorgio
    Ettrup, Anders
    Christoffersen, Cecilie Laurberg
    Josiassen, Mette Krog
    Phul, Ravinder
    Sperling, Bjorn
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (01):
12345